Cochrane · systematic review · CD001908
Tiagabine add‐on therapy for drug‐resistant focal epilepsy
Bresnahan, R, Martin‐McGill, KJ, Hutton, JL, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 4 · 57.1%High 1 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyTiagabine compared to placebo control for drug‐resistant focal epilepsy
Population: People with drug‐resistant focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
50% or greater reduction in seizure frequency (Intention‐to‐treat analysis) Tiagabine vs placebo control | RR 3.16 [1.97, 5.07] | 3 studies · 769 participants | High |
Treatment withdrawal Tiagabine vs placebo control | RR 1.81 [1.25, 2.62] | 3 studies · 769 participants | Moderate Downgraded: imprecision |
Dizziness Tiagabine vs placebo control | RR 1.69 [1.13, 2.51] | 3 studies · 769 participants | Moderate Downgraded: imprecision |
Fatigue Tiagabine vs placebo control | RR 1.38 [0.89, 2.14] | 3 studies · 769 participants | Moderate Downgraded: imprecision |
Nausea Tiagabine vs placebo control | RR 1.24 [0.69, 2.22] | 3 studies · 769 participants | Low Downgraded: imprecision, publication bias |
Somnolence Tiagabine vs placebo control | RR 1.18 [0.76, 1.83] | 3 studies · 769 participants | Moderate Downgraded: imprecision |
Tremor Tiagabine vs placebo control | RR 4.56 [1, 20.94] | 1 study · 297 participants | Low Downgraded: imprecision, publication bias |
Tiagabine versus placebo control—50% or greater reduction in seizure frequency for drug‐resistant partial epilepsy
Population: patients with drug‐resistant partial epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intention‐to‐treat analysis Tiagabine vs placebo control—50% or greater reduction | RR 3.16 [1.97, 5.07] | 769 participants | High |
Worst‐case scenario Tiagabine vs placebo control—50% or greater reduction | RR 2.7 [1.75, 4.19] | 769 participants | High |
Best‐case scenario Tiagabine vs placebo control—50% or greater reduction | RR 3.32 [2.08, 5.32] | 769 participants | High |
Tiagabine versus placebo: 50% seizure reduction
Population: Patients with drug‐resistant partial epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intention‐to‐treat analysis Tiagabine vs placebo: 50% seizure reduction | RR 3.16 [1.97, 5.07] | 3 studies · 769 participants | High |
Worst case scenario Tiagabine vs placebo: 50% seizure reduction | RR 2.7 [1.75, 4.19] | 3 studies · 769 participants | High |
Best case scenario Tiagabine vs placebo: 50% seizure reduction | RR 3.32 [2.08, 5.32] | 3 studies · 769 participants | High |